Juventas Therapeutics, Inc.
http://www.juventasinc.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Juventas Therapeutics, Inc.
Financing Quarterly Statistics, Q4 2022
During Q4, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $1.9bn; while in vitro diagnostic firms and research tools players raised $848m.
MorphoSys Upbeat Despite Partner Failures In Alzheimer's And Rheumatoid Arthritis
Monjuvi is still struggling to make progress commercially and the hopes of lucrative royalty streams from partners Roche and GSK have dried up but MorphoSys is keeping faith in its fully owned pipeline.
With $120m, HI-Bio Aims To Rapidly Prove Approach To Immune-Mediated Diseases
Human Immunology Biosciences (HI-Bio) launched with $120m and two candidates from MorphoSys, including the CD38 inhibitor felzartamab already in the clinic for immune-mediated kidney diseases.
Finance Watch: Biopharma VC Funding Dips In Q3, Remains Relatively High For Year
Private Company Edition: Third quarter venture capital funding for biopharmaceutical firms fell from Q2, but activity remains near all-time highs year-to-date. Several companies announced VC financings in early October, including Ascidian, which launched with $50m in series A financing.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- AcelleRX Therapeutics Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice